Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tissue inhibitor of metalloproteinase 2 is a secreted protein that belongs to the family of natural inhibitors regulating matrix metalloproteinases—enzymes responsible for degrading components of the extracellular matrix. Unlike other family members, it not only inhibits several MMPs but also uniquely suppresses endothelial cell proliferation and modulates angiogenesis. It plays critical roles in maintaining tissue homeostasis during development, wound healing, tumor invasion/metastasis suppression, cardiovascular health, and neural plasticity. The gene encoding this protein is located on chromosome 17p13.
Drugs or molecules that interact with this target typically act by inhibiting or modulating matrix metalloproteinases through direct binding to their catalytic domains, thereby preventing extracellular matrix degradation. Some agents may also block the activation pathway involving MT1-MMP/TIMP-2 complexes for pro-MMP activation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tissue inhibitor of metalloproteinase 2 (TIMP-2).